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Continuous glucose monitoring systems (CGMS) are relatively 
new technology that measures interstitial glucose every 5 min-
ute over a period of 72 hours [1]. Continuous glucose monitor-
ing by CGMS provides accurate data to patients and physicians 
about blood glucose variability during the measurement peri-
od. Two types of CGMS devices, intended for professional and 
personal use, are available. Professional devices allow physi-
cians to download and analyze data and for use in clinical de-
cision making. Personal devices allow patients to monitor real 
time glucose data and use such data for self-monitoring and 
medication adjustments. For this reason, the American Asso-
ciation of Clinical Endocrinologists has recommended the use 
of personal devices for glucose control and prevention of hy-
poglycemia in patients with type 1 diabetes [2,3] and pregnan-
cy with diabetes [4,5]. 
  The article, “The correlation and accuracy of glucose levels 
between interstitial fluid and venous plasma by continuous 
glucose monitoring system” [6] clearly showed a glucose time 
lag between blood levels and subcutaneous interstitial levels. 
Blood and interstitial fluid had different peak times and peak 
values after meal loading, but the trends of glucose excursion 
were very similar. In addition, CGMS data showed delayed 
peaks and lowered peak values compared to venous blood 
sugar levels after the ingestion of different kinds of food. These 
lags between the two compartments did not differ by food. 
The use of CGMS devices, which provide accurate control and 
monitoring of blood glucose levels, is suitable for use in uncon-
trolled diabetic patients and to help physicians make decisions 
regarding treatment modalities. 
  In the treatment of diabetes, glucose variability, especially 
postprandial hyperglycemia, is a major risk factor for cardio-
vascular complications. By using CGMS devices, clinicians can 
easily access glucose variability in patients. Although patients 
more easily achieved target HbA1c levels when practicing self 
monitoring of glucose using the CGMS device than by other 
methods, systemic reviews comparing the results of CGMS 
use and intermittent fingertip glucose monitoring do not indi-
cate significantly superior benefits of CGMS. However, they do 
support the improved detection of asymptomatic nocturnal 
hypoglycemia [7].
  CGMS systems offer many advantages to patients and phy-
sicians. However, the sensitivity of glucose sensing decreases 
over time. After 3 to 5 days, the sensing amplitude of CGMS 
sensors becomes unreliable. The accuracy of sensors is affected 
by localized tissue reactions and fibrous encapsulation [8]. For 
these reasons, patients should calibrate sensing amplitudes 
through comparisons with fingertip glucose values regularly. 
Methods of blocking fibrous tissue aggregation and reducing 
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tissue reactions, such as corticosteroid sprays or anticancer drug 
coatings, were used in attempts to address these problems 
[9,10]. Also, if we placed the sensor in subcutaneous space 
during continuous monitoring, small glucose diffusion gap 
from blood level to subcutaneous tissue fluid was another lim-
itation. 
  Recently, ubiquitous health systems have been introduced 
to help outpatients to control their blood sugar levels. If patients 
send their blood glucose profiles to physicians over the inter-
net, their physicians can provide advice to meet their patients’ 
needs. The use of CGMS systems connected to Internet net-
works has the potential to provide effective, evidence-based 
support to clinicians in their daily efforts to optimize glycemic 
control [11].
  The closed loop pump is a state of the art technology [12,13]. 
But major pitfall of this closed loop pump is sensing problems 
of glucose sensor and limited space of insulin reservoir in trans-
planted pump. Closed loop pumps are expected to replace open 
loop pumps and decrease the pain associated with insulin in-
jections. Permanent usable blood glucose sensors and intersti-
tial glucose sensors are also expected to be developed [9,10]. 
Rapid development of information technology devices and 
techniques will solve the relevant technological problems, and 
closed loop systems will be available to patients in the future. 
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